Matthew Burton, MD
Neurology · Huntington, WVNPI 1144756180
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,591 of the $3,142 with a category attached, or 82.5%. 19 manufacturers reported payments, led by AbbVie at 40.1% of the total. 2025 is the largest year on record at $1,634, 3.4 times the $480 reported in 2021.
Across 146 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boston Scientific$656
- Neurocrine Biosciences, Inc.$287
- Acadia Pharmaceuticals Inc$211
- Biogen$137
- Merz Pharmaceuticals, LLC$101
- plus $489 from 13 others
What the payments were for
- Travel & lodging$48015%
- Food & beverage$2,59182%
- Education$712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $1,261 |
| Boston Scientific | 3 | $656 |
| Neurocrine Biosciences, Inc. | 17 | $287 |
| Acadia Pharmaceuticals Inc | 7 | $211 |
| Biogen | 7 | $137 |
| Merz Pharmaceuticals, LLC | 5 | $101 |
| Teva Pharmaceuticals USA, Inc. | 1 | $67 |
| Neurelis, Inc. | 3 | $66 |
| Supernus Pharmaceuticals, Inc. | 3 | $62 |
| Kyowa Kirin, Inc. | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| UCB, Inc. | 1 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Lundbeck LLC | 2 | $30 |
| Argenx US, Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$480
- GENERAL DBS$142
- INGREZZA$139
How this compares
$3,142 in reported general payments places this provider in the 65th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $199,181 |
| NuplazidPimavanserin Tartrate | 28 | $150,092 |
| RytaryCarbidopa/Levodopa | 43 | $49,893 |
| GocovriAmantadine Hcl | 15 | $41,942 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 473 | $18,771 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 36 | $11,276 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 105 | $9,124 |
| Entacapone | 22 | $4,229 |
| Selegiline Hcl | 26 | $3,692 |
| AmantadineAmantadine Hcl | 46 | $2,624 |
| Gabapentin | 100 | $2,152 |
| Ropinirole Hcl | 60 | $2,002 |
| Rasagiline Mesylate | 17 | $1,966 |
| Primidone | 71 | $1,189 |
| Propranolol Hcl ErPropranolol Hcl | 23 | $1,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $67 | $199,18123 claims |
| Acadia Pharmaceuticals IncNuplazid | $211 | $150,09228 claims |
| Amneal Pharmaceuticals LLCRytary | $37 | $49,89343 claims |
| MDD US Operations, LLCGocovri | $22 | $41,94215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 93 neurology providers in West Virginia.
Other neurology in Huntington
- Paul FergusonHuntington$649K
- Ronald BareboHuntington$28K
- Lindsay LittlehalesHuntington$17K
- Samrina HanifHuntington$12K
- Suresh KumarHuntington$12K
- Kathryn ThorntonHuntington$3K
- Justin NolteHuntington$2K
- Christopher BurrellHuntington$1K
- Dharampreet SinghHuntington$971
- Gabrielle ConwayHuntington$914
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.